Yongbao Wei, Yongbao Wei, Ruochen Zhang, Ruochen Zhang, Chenbo Yu, Chenbo Yu, . . . Jianhui Chen. (2023). Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: A two-center's real-world study. Frontiers Media S.A..
Chicago Style (17th ed.) CitationYongbao Wei, et al. Disitamab Vedotin in Combination with Immune Checkpoint Inhibitors for Locally and Locally Advanced Bladder Urothelial Carcinoma: A Two-center's Real-world Study. Frontiers Media S.A., 2023.
MLA (9th ed.) CitationYongbao Wei, et al. Disitamab Vedotin in Combination with Immune Checkpoint Inhibitors for Locally and Locally Advanced Bladder Urothelial Carcinoma: A Two-center's Real-world Study. Frontiers Media S.A., 2023.
Warning: These citations may not always be 100% accurate.